On January 10, 2025 Defence Therapeutics Inc. ("Defence" or the "Company"), (CSE: DTC, OTCQB: DTCFF, FSE: DTC) a Canadian biopharmaceutical company developing radiopharmaceuticals and ADC products using its proprietary platform and drug delivery technologies in addition to novel immune-oncology vaccines, reported its participation to the Biotech ShowcaseTM conference next week in San Francisco during the J.P. Morgan Healthcare Conference to meet with industry leaders, partners and potential investors (Press release, Defence Therapeutics, JAN 10, 2025, View Source;utm_medium=rss&utm_campaign=defence-to-connect-with-industry-leaders-and-potential-partners-during-the-jp-morgan-healthcare-conference-in-san-francisco-plans-to-expand-the-next-generation-of-radio-immuno-conjugates-in-2025 [SID1234649649]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The Biotech Showcase is a premier investor conference committed to creating a platform for biotech companies, offering them a unique opportunity to showcase their innovation and engage one-to-one with investors and biopharmaceuticals executives. The life science conference is taking place from January 13-16 in San Francisco during the JP Morgan Healthcare Conference which is the premier healthcare investment symposium attracting thousands of industry leaders and investors.
"Our CSO, Dr. Maxime Parisotto, and I will be actively participating in the healthcare conference and meetings related in San Francisco to meet with global industry leaders, potential partners and investors to reinforce our network in the US ecosystem and more importantly to clearly demonstrate the strength and importance of our proprietary Accum technology platform in the US life science market. The Accum technology platform has a great potential to play a pivotal role to improve ADCs and in the development of targeted radiopharmaceutical therapies, which we are fully dedicated to expanding in 2025" says Mr. Plouffe, CEO and president of Defence Therapeutics.
The Company is also pleased to announce the closing of the 1st tranche of its previously announced non-brokered private placement (the "Offering") of units of the Company (the "Units") at a price of $0.60 per Unit for aggregate gross proceeds of $300,000 (the "Closing"). Each Unit consists of one common share in the capital of the Company (each, a "Share") and one common share purchase warrant (each whole, a "Warrant"). Each Warrant is exercisable to acquire one additional Share at an exercise price of $0.75 per Share for a period of 24 months from the date of the Closing (the "Warrant Expiry Date").
In connection with the Closing, the Company paid a cash finder’s fee of $24,000 and issued 40,000 finder’s warrants (the "Finder’s Warrants") to certain qualified arm’s length finder. Each Finder’s Warrant is exercisable into one Share at an exercise price of $0.75 per Share on or before the Warrant Expiry Date.
The Company intends to use the net proceeds of the Offering to advance its preclinical and clinical programs and for general working capital. All securities issued in connection with the Offering are subject to a statutory hold period of four months plus a day from their date of issue in accordance with applicable securities legislation.